Stock Market Reviews

CSTL (Castle Biosciences, Inc.) News

Get the latest news, insights, and market updates on CSTL (Castle Biosciences, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold
  Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.
  Jan 28, 2026 - $CSTL
• SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
  SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
  Jan 27, 2026 - $CSTL
• Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice
  Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Jan 23, 2026 - $CSTL
• Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth
  Guidance update and volume growth set the stage Castle Biosciences (CSTL) issued new earnings guidance for the fourth quarter and full year 2025, expecting revenue above US$340 million and reporting higher test volumes for its core DecisionDx-Melanoma and TissueCypher Barrett’s Esophagus franchises. See our latest analysis for Castle Biosciences. That guidance update lands after a sharp 72.47% 90 day share price return. The 1 year total shareholder return of 30.05% contrasts with a 5 year...
  Jan 12, 2026 - $CSTL
• The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook
  Castle Biosciences recently reported preliminary, unaudited fourth-quarter and full-year 2025 results, highlighting very large growth in core test volumes for DecisionDx-Melanoma and TissueCypher and expecting 2025 revenue to exceed US$340 million, above prior guidance. The company also launched its AdvanceAD-Tx test for moderate-to-severe atopic dermatitis, signaling a move into a new dermatology segment that could broaden its addressable market and further diversify its test...
  Jan 12, 2026 - $CSTL
• Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
  2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patie
  Jan 11, 2026 - $CSTL
• INSM Stock Up 78% in 6 Months: Here's What You Need to Know
  Insmed shares surged on FDA and EU approvals of Brinsupri, strong uptake, and a growing pipeline which fueled optimism around its revenue outlook.
  Jan 2, 2026 - $CSTL
• AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation
  Axsome stock jumps as the FDA grants priority review to sNDA for AXS-05 in Alzheimer's agitation, with a decision expected April 30, 2026.
  Jan 2, 2026 - $CSTL
• RARE Rises on Completion of Rolling Submission for AAV Gene Therapy
  Ultragenyx jumps after completing rolling BLA submission to the FDA for DTX401, an AAV gene therapy that could become the first approved treatment for GSDIa.
  Dec 31, 2025 - $CSTL
• RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint
  Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.
  Dec 30, 2025 - $CSTL